Table 3.
Survival outcomes and additional findings of included studies.
| Median OS (months) |
|||||
|---|---|---|---|---|---|
| Reference | NACT Overall | NACT + IDS subgroup | PDS | Additional findings | |
| Bogani et al., 2019 | – | 16.7 | 18 | p = 0.35 | |
| de Lange et al., 2019 | 27 | NR | – | •Subgroup analysis of median OS (months) by extent of debulking Complete/optimal = 41 Suboptimal = 16 No surgery = 13 |
|
| Eto et al., 2013 | 12 | 21 | 21 | p = 0.84 for NACT+IDS vs. PDS | • Median OS for NACT patients who did not receive IDS = 7 months |
| Holman et al., 2017 | 20.4 | NR | – | • Subgroup analysis of median OS (months) by treatment modalities PDS + adj. CT = 30.8 PDS + adj. RT = 38.3 PDS + adj. CT + adj. RT = 48.8 |
|
| Khouri et al., 2019 | NR | 16 | – | • Improved median OS associated with IDS vs. no IDS (16 months vs. 6 months, p = 0.037) • Improved median OS associated with partial response to NACT vs. no response (15 months vs. 5 months, p = 0.015) |
|
| Rajkumar et al., 2019 | – | 29 | 22.5 | p = 0.57, HR=1.26, 95%CI (0.56-2.85) | • Subgroup analysis of median OS (months) by extent of debulking Complete/optimal = 29 Suboptimal = 17.5 |
| Tobias et al., 2020 | 19 (95% CI: 17-21) |
NR | 25 (95% CI: 24-27) |
• Survival curves of overall NACT and overall PDS arms cross after 3 months • Survival curves of NACT+IDS and PDS+adj. CT arms cross after 8 months |
|
| Vandenput et al., 2009 | 23 | NR | – | • Median OS for NACT patients who did not undergo IDS (n=6) = 12 months | |
| Wilkinson-Ryan et al., 2015 | – | 17.3 | 20.7 | p = 0.23 | |
NACT = neoadjuvant chemotherapy, PDS = primary debulking surgery, adj. CT = adjuvant chemotherapy, adj. RT = adjuvant radiotherapy, NR = not reported.